Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Eikon Therapeutics, Inc.

News headline image
Eikon Therapeutics to Join the Russell 3000® Index
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
From Eikon Therapeutics, Inc.
Via GlobeNewswire
Tickers EIKN
News headline image
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
From Eikon Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer
From Eikon Therapeutics, Inc.
Via Business Wire
News headline image
Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery
From Eikon Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.